AXIM AXIM BIOTECHNOLOGIES, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1514946 · Fiscal year ends 12/31
Financial factors as of 2022-09-30 (2022Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-89.0%
TTM net income YoY-29.0%
TTM EPS YoY282.5%
Revenue 3-yr CAGR-67.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-182,235.4%
Net margin-218,733.8%
FCF margin—
EBITDA margin-142,796.3%
Returns
ROE-10,021.6%
ROA-143.0%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets197.8%
Debt / equity—
Current ratio0.08x
Interest coverage-7.07x
Cash quality & payout
Operating cash flow / net income0.19x
Accruals ratio-116.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $39,518 | $8,875 |
| R&D expense | $125,496 | $153,697 |
| SG&A expense | $2.24M | $4.08M |
| Operating income | -$2.75M | -$4.65M |
| Interest expense | $140,000 | $261,537 |
| Pretax income | -$8.06M | -$6.24M |
| Income tax | $0 | $0 |
| Net income | -$8.06M | -$6.24M |
| EBITDA | -$2.32M | -$4.23M |
| EPS (basic) | -0.04 | -0.04 |
| EPS (diluted) | -0.04 | -0.04 |
| Banking | ||
| Noninterest expense | $0 | $177,500 |
| Balance sheet | ||
| Cash & equivalents | $156,457 | $47,282 |
| Current assets | $156,457 | $103,979 |
| PP&E, net | $134,067 | $93,840 |
| Intangibles | — | $3.99M |
| Total assets | $4.12M | $4.21M |
| Current liabilities | $5.98M | $3.39M |
| Short-term debt | $94,829 | $19,789 |
| Long-term debt | $137,044 | — |
| Total debt | $231,873 | — |
| Total liabilities | $11.78M | $9.04M |
| Shareholders' equity | -$7.66M | -$4.83M |
| Net debt | $75,416 | — |
| Shares outstanding | 245.93M | 192.44M |
| Cash flow statement | ||
| Operating cash flow | -$1.03M | -$2.04M |
| Capital expenditure | $0 | $8,710 |
| Free cash flow | -$1.03M | -$2.05M |
| Investing cash flow | $0 | -$8,710 |
| Financing cash flow | $1.14M | $1.65M |
| Depreciation & amortization | $427,019 | $426,126 |
| Stock-based compensation | $197,727 | $1.11M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.